JP2019529469A5 - - Google Patents

Download PDF

Info

Publication number
JP2019529469A5
JP2019529469A5 JP2019516249A JP2019516249A JP2019529469A5 JP 2019529469 A5 JP2019529469 A5 JP 2019529469A5 JP 2019516249 A JP2019516249 A JP 2019516249A JP 2019516249 A JP2019516249 A JP 2019516249A JP 2019529469 A5 JP2019529469 A5 JP 2019529469A5
Authority
JP
Japan
Prior art keywords
alkyl
salt
compound
compound according
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019516249A
Other languages
English (en)
Japanese (ja)
Other versions
JP7094275B2 (ja
JP2019529469A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/055973 external-priority patent/WO2018060926A1/en
Publication of JP2019529469A publication Critical patent/JP2019529469A/ja
Publication of JP2019529469A5 publication Critical patent/JP2019529469A5/ja
Application granted granted Critical
Publication of JP7094275B2 publication Critical patent/JP7094275B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019516249A 2016-09-28 2017-09-28 ベータラクタマーゼ阻害剤 Expired - Fee Related JP7094275B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662401022P 2016-09-28 2016-09-28
US62/401,022 2016-09-28
PCT/IB2017/055973 WO2018060926A1 (en) 2016-09-28 2017-09-28 Beta-lactamase inhibitors

Publications (3)

Publication Number Publication Date
JP2019529469A JP2019529469A (ja) 2019-10-17
JP2019529469A5 true JP2019529469A5 (enExample) 2021-03-25
JP7094275B2 JP7094275B2 (ja) 2022-07-01

Family

ID=60191429

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019516249A Expired - Fee Related JP7094275B2 (ja) 2016-09-28 2017-09-28 ベータラクタマーゼ阻害剤

Country Status (42)

Country Link
US (2) US10597396B2 (enExample)
EP (2) EP3698796B1 (enExample)
JP (1) JP7094275B2 (enExample)
KR (1) KR20190058492A (enExample)
CN (1) CN109843894B (enExample)
AR (1) AR109737A1 (enExample)
AU (1) AU2017335405B2 (enExample)
BR (1) BR112019002195A2 (enExample)
CA (1) CA3030373A1 (enExample)
CL (1) CL2019000232A1 (enExample)
CO (1) CO2019001995A2 (enExample)
CR (1) CR20190104A (enExample)
CU (1) CU24562B1 (enExample)
CY (1) CY1123062T1 (enExample)
DK (1) DK3519419T3 (enExample)
EA (1) EA036675B1 (enExample)
EC (1) ECSP19016602A (enExample)
ES (2) ES2801874T3 (enExample)
HR (1) HRP20200986T1 (enExample)
HU (1) HUE049788T2 (enExample)
IL (1) IL265626B (enExample)
JO (1) JOP20190061A1 (enExample)
LT (1) LT3519419T (enExample)
MA (2) MA50427A (enExample)
MD (1) MD3519419T2 (enExample)
ME (1) ME03735B (enExample)
MX (1) MX380076B (enExample)
MY (1) MY189632A (enExample)
PE (1) PE20190459A1 (enExample)
PH (1) PH12019500331A1 (enExample)
PL (1) PL3519419T3 (enExample)
PT (1) PT3519419T (enExample)
RS (1) RS60483B1 (enExample)
SG (1) SG11201900394SA (enExample)
SI (1) SI3519419T1 (enExample)
SM (1) SMT202000343T1 (enExample)
TN (1) TN2019000020A1 (enExample)
TW (1) TWI746652B (enExample)
UA (1) UA123833C2 (enExample)
UY (1) UY37424A (enExample)
WO (1) WO2018060926A1 (enExample)
ZA (1) ZA201900137B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190061A1 (ar) 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
CN119707784A (zh) * 2018-09-21 2025-03-28 株式会社Api 氨基酸衍生物的制备方法
US20240390335A1 (en) * 2021-11-09 2024-11-28 Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences Pharmaceutical composition containing beta-lactam compound and use thereof
CN115368261A (zh) * 2022-07-29 2022-11-22 武汉理工大学 N-烯丙基-n-苄基-2-(苄基氨基)乙酰胺的合成方法

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2116183B (en) 1982-03-03 1985-06-05 Genentech Inc Human antithrombin iii dna sequences therefore expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby a process for expressing human antithrombin iii and pharmaceutical compositions comprising it
CA2143519A1 (en) * 1994-03-11 1995-09-12 F. Hoffmann-La Roche Ag Beta-lactams
DK0920505T3 (da) 1996-08-16 2008-09-08 Schering Corp Pattedyrcelleoverfladeantigener og tilhörende reagenser
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
CA2308114A1 (en) 1997-10-21 1999-04-29 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
JP2002502607A (ja) 1998-02-09 2002-01-29 ジェネンテク・インコーポレイテッド 新規な腫瘍壊死因子レセプター相同体及びそれをコードする核酸
ATE376837T1 (de) 1999-07-12 2007-11-15 Genentech Inc Stimulierung oder hemmung von angiogenese und herzvaskularisierung mit tumor nekrose faktor ligand/rezeptor homologen
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2848210B1 (fr) 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
AU2004244626A1 (en) 2003-05-23 2004-12-09 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
EP1660126A1 (en) 2003-07-11 2006-05-31 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
EP1692318A4 (en) 2003-12-02 2008-04-02 Genzyme Corp COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF LUNG CANCER
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
EP1765402A2 (en) 2004-06-04 2007-03-28 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール,インク. Gitr結合分子およびその使用
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
WO2007133822A1 (en) 2006-01-19 2007-11-22 Genzyme Corporation Gitr antibodies for the treatment of cancer
WO2008039420A2 (en) 2006-09-27 2008-04-03 Merck & Co., Inc. Novel inhibitors of beta-lactamase
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
JP5038509B2 (ja) * 2008-01-18 2012-10-03 メルク・シャープ・エンド・ドーム・コーポレイション β−ラクタマーゼ阻害剤
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
JP2011526794A (ja) 2008-07-02 2011-10-20 エマージェント プロダクト デベロップメント シアトル, エルエルシー TGF−βアンタゴニスト多重標的結合性分子
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
JPWO2010030002A1 (ja) 2008-09-12 2012-02-02 国立大学法人三重大学 外来性gitrリガンド発現細胞
FR2936951B1 (fr) 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
WO2010126820A2 (en) 2009-04-30 2010-11-04 Merck Sharp & Dohme Corp. Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
IN2015DN02826A (enExample) 2009-09-03 2015-09-11 Merck Sharp & Dohme
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
US20130089554A1 (en) 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
CN103649088B (zh) * 2011-08-30 2016-05-11 沃克哈特有限公司 1, 6- 二氮杂双环[3, 2, 1]辛- 7- 酮衍生物及其在治疗细菌感染中的用途
BR112014003476A2 (pt) 2011-09-13 2017-03-01 Wockhardt Ltd compostos contendo nitrogênio e seu uso
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US9025112B2 (en) 2012-02-02 2015-05-05 Apple Inc. Display with color mixing prevention structures
EP2814483A2 (en) 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
TW201343645A (zh) 2012-03-30 2013-11-01 Cubist Pharm Inc 1,3,4-□二唑及1,3,4-噻二唑β-內醯胺酶抑制劑
JP2015512419A (ja) 2012-03-30 2015-04-27 キュービスト ファーマシューティカルズ, インコーポレイテッド イソオキザゾールβ−ラクタマーゼ阻害剤
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
ES2672100T3 (es) 2012-08-25 2018-06-12 Wockhardt Limited Derivados de 1,6-diazabiciclo[3,2,1]octano-7-ona y su uso en el tratamiento de infecciones bacterianas
WO2014141132A1 (en) 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
WO2015052682A1 (en) * 2013-10-11 2015-04-16 Wockhardt Limited Nitrogen containing compounds and their use
WO2016116788A1 (en) * 2015-01-24 2016-07-28 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
EP3277277B1 (en) * 2015-04-03 2021-01-06 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
EP3075381A1 (en) * 2015-04-03 2016-10-05 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
JOP20190061A1 (ar) 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز

Similar Documents

Publication Publication Date Title
IL272115B (en) An aryl-phosphorus-oxygen compound as an egfr kinase inhibitor
EA202193007A1 (ru) Соединения пирролидина
EA202092169A1 (ru) ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ АМИНОПРОПИОНАТНЫХ СОЕДИНЕНИЙ В ЛЕЧЕНИИ ИНФЕКЦИИ SARS-CoV-2
MX385731B (es) Compuestos de biaril-monobactam y métodos de uso de los mismos para el tratamiento de infecciones bacterianas.
JP2016516020A5 (enExample)
JOP20200130B1 (ar) مركبات كرومان مونوباكتام لعلاج العدوى البكتيرية
RU2014143821A (ru) 1, 3, 4-ОКСАДИАЗОЛЬНЫЕ И 1, 3, 4-ТИАДИАЗОЛЬНЫЕ ИНГИБИТОРЫ β-ЛАКТАМАЗЫ
JP2015511232A5 (enExample)
HRP20211331T1 (hr) Inhibitor površinskog antigena hepatitis b virusa
BR112015021027A8 (pt) compostos terapêuticos, seus usos, e composições farmacêuticas
JP2012502974A5 (enExample)
EA025252B1 (ru) Способы и соединения для лечения вирусных инфекций paramyxoviridae
RU2018114480A (ru) Соли и твердые формы монобактамного антибиотика
JP2016514192A5 (enExample)
AR107030A1 (es) Inhibidores aza-bencimidazol de pad4
HRP20200894T1 (hr) Novi antibakterijski spojevi
RU2019121926A (ru) Ингибитор CDK4/6
RU2015132569A (ru) Полимиксины, композиции с ними, способы получения и способы применения
JP2021528449A5 (enExample)
JP2013515037A5 (enExample)
HRP20200986T1 (hr) Inhibitori beta-laktamaze
JP2018523675A5 (enExample)
JP2016501844A5 (enExample)
CN109311881A (zh) 新型β-内酰胺酶抑制剂
CR20210394A (es) Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéuticas del mismo